Expert opinion paper on the treatment of hemophilia B with albutrepenonacog alfa


Por: Roman, MTA, Benitez, O, Canaro, MI, Fernandez, MFL, Jaime, FLJ, Arranz, JM, Nunez, R, Lopez, MR, Aisa, CS, Jimenez-Yuste, V

Publicada: 2 sep 2021 Ahead of Print: 1 jul 2021
Resumen:
Introduction: Current guidelines recommend prophylactic treatment of hemophilia B with the missing coagulation factor IX, either with standard half-life or extended half-life products. Extended half-life products have half-lives three to six times longer than the former, allowing a reduction in the number of weekly injections and therefore, potentially impacting on treatment adherence and quality of life. Albutrepenonacog alfa is an extended half-life fusion protein of coagulation factor IX with recombinant human albumin, indicated for both on-demand and prophylactic treatment for bleeding in patients with hemophilia B of all ages. Areas covered: The authors review the clinical and pharmacokinetic characteristics of albutrepenonacog alfa, as well as the available information regarding trough levels and real-world evidence. Given the availability of other factor IX products in the market, indirect comparisons of clinical and pharmacokinetic characteristics are presented. Expert opinion: The authors exhibit their expert opinion on which patient profiles are candidates for prophylactic treatment with albutrepenonacog alfa, and on the management of patients in terms of dosing, regimens of administration and protocols for switching the treatment.

Filiaciones:
Roman, MTA:
 Hosp Univ La Paz Idipaz, Hematol Dept, Haemophilia Unit, Paseo Castellana 261, Madrid 28046, Spain

Benitez, O:
 Hosp Valle De Hebron, Hematol Dept, Haemophilia Unit, Barcelona, Spain

Canaro, MI:
 Hosp Univ Son Espases, Hematol Serv, Palma De Mallorca, Spain

Fernandez, MFL:
 Hosp Materno Infantil INIBIC CHUAC, Hematol & Hemotherapy Serv, A Couna, Spain

Jaime, FLJ:
 Hosp Univ Reg Malaga, Hematol Dept, Malaga, Spain

Arranz, JM:
 Hosp Santa Creu & Sant Pau, Thrombosis & Hemostasis Unit, Barcelona, Spain

Nunez, R:
 Hosp Univ Virgen Rocio, Hematol Serv, Seville, Spain

Lopez, MR:
 Hosp Alvaro Conqueiro, Hematol & Hemotherapy Serv, Vigo, Spain

Aisa, CS:
 Hosp Univ Cruces, Hematol & Hemotherapy Serv, Hemostasis & Thrombosis Sect, Baracaldo, Spain

Jimenez-Yuste, V:
 Hosp Univ La Paz IdiPaz, Hematololy Dept, Madrid, Spain
ISSN: 14712598
Editorial
TAYLOR & FRANCIS LTD, 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 21 Número: 9
Páginas: 1165-1171
WOS Id: 000670086900001
ID de PubMed: 34225551
imagen hybrid

MÉTRICAS